Title:
6-AMINOPYRAZOLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/032987
Kind Code:
A1
Abstract:
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A compound represented by formula [IA] or a pharmaceutically acceptable salt thereof. [IA] (In the formula, the partial structure [2] is a structure represented by formula [3] (in the formula, R4 is hydrogen or a C1-4 alkyl (where the alkyl may be substituted with hydroxy or cyano)), and a cyclic group CyA is a group represented by formula [5] (in the formula, R6 and R7 are each independently hydrogen, hydroxy, cyano, C1-6 alkyl, or the like, R8 and R9 are each independently hydrogen, C1-4 alkyl, or C1-4 haloalkyl, and R10 is hydrogen, cyano, C1-6 alkyl, or the like), R1 is hydrogen or C1-4 alkyl, R2A and R3A are each independently hydrogen, C1-6 alkyl, or the like, or R2A and R3A together with a nitrogen atom to which they are bonded may form a 4-membered to 7-membered heterocycloalkyl, or the like, to which a -NR2AR3A group may be substituted.)
Inventors:
OHBA YUSUKE (JP)
ADACHI KAORU (JP)
NISHIMARU TATSUYA (JP)
SAKURAI KENTARO (JP)
OGOSHI YOSUKE (JP)
SATO SHIMPEI (JP)
ADACHI KAORU (JP)
NISHIMARU TATSUYA (JP)
SAKURAI KENTARO (JP)
OGOSHI YOSUKE (JP)
SATO SHIMPEI (JP)
Application Number:
PCT/JP2022/032606
Publication Date:
March 09, 2023
Filing Date:
August 30, 2022
Export Citation:
Assignee:
JAPAN TOBACCO INC (JP)
International Classes:
C07D487/04; A61K31/519; A61K31/5355; A61K31/5377; A61K31/5386; A61K31/541; A61K31/55; A61K31/551; A61K31/553; A61P1/00; A61P1/04; A61P1/16; A61P3/00; A61P9/00; A61P9/10; A61P13/12; A61P17/00; A61P19/02; A61P19/06; A61P25/00; A61P25/28; A61P27/04; A61P29/00; A61P37/02; A61P37/06; A61P37/08; A61P43/00; C07D519/00
Domestic Patent References:
| WO2017205766A1 | 2017-11-30 | |||
| WO2020150114A1 | 2020-07-23 | |||
| WO2020150115A1 | 2020-07-23 |
Foreign References:
| JP2014511885A | 2014-05-19 |
Other References:
SHISHOO C. J., RAVIKUMAR T., JAIN K. S., RATHOD I. S., GANDHI T. P., SATIA M. C.: "ChemInform Abstract: Synthesis of Novel 1,2-(Un) Substituted-3-amino-5-aryl-6-arylaminopyrazolo [3,4-d]pyrimidin-4(5H)-ones and Their Biological Activities.", CHEMINFORM, ELECTROCHEMICAL SOCIETY, vol. 31, no. 10, 7 March 2000 (2000-03-07), pages no - no, XP093041997, ISSN: 0931-7597, DOI: 10.1002/chin.200010142
ANDERSSON, A ET AL.: "Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis", J LEUKOC BIOL., vol. 84, no. 5, 2008, pages 1248 - 55, XP002659931, DOI: 10.1189/jlb.1207844
VOET, S ET AL.: "A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation", NAT COMMUN., vol. 9, no. 1, 2018, pages 2036, XP055864050, DOI: 10.1038/s41467-018-04376-5
POLITIS, M ET AL.: "Increased PK11195 PET binding in the cortex of patients with MS correlates with disability", NEUROLOGY, vol. 79, no. 6, 2012, pages 523 - 30
HERNANDEZ-PEDRO, N ET AL.: "PAMP-DAMPs interactions mediates development and progression of multiple sclerosis", FRONT BIOSCI (SCHOL ED, vol. 8, 2016, pages 13 - 28
DENIS, G ET AL.: "NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses", J IMMUNOL., vol. 185, no. 2, 2010, pages 974 - 981
JHA, S ET AL.: "The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18", J NEUROSCI., vol. 30, no. 47, 2010, pages 15811 - 20, XP002661303, DOI: 10.1523/jneurosci.4088-10.2010
GUO, C ET AL.: "Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis", ACS CHEM NEUROSCI., vol. 8, no. 10, 2017, pages 2194 - 2201, XP055509994, DOI: 10.1021/acschemneuro.7b00124
AKOSUA VILAYSANE ET AL.: "The NLRP3 Inflammasome Promotes Renal Inflammation and Contributes to CKD", J AM SOC NEPHROL., vol. 21, no. 10, October 2010 (2010-10-01), pages 1732 - 1744
SHAHZAD K ET AL.: "Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy", KIDNEY INT., vol. 87, no. 1, January 2015 (2015-01-01), pages 74 - 84, XP055881761, DOI: 10.1038/ki.2014.271
GONG W ET AL.: "NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy", AM J PHYSIOL RENAL PHYSIOL., vol. 310, no. 10, 15 May 2016 (2016-05-15), pages F1081 - 8
RANSON N ET AL.: "NLRP3-dependent and -independent processing Interleiukin-ip in active Ulcerative colitis", INT J MOL SCI, vol. 20, 2018, pages E57
MAO L ET AL.: "Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease", J CLIN INVEST, vol. 128, 2018, pages 1793 - 1806
BAUER C. ET AL.: "Protective and aggravating effects of NLRP3 inlammasome activation in IBD models : influence of genetic and environmental factors", DIG.DIS, vol. 30, 2012, pages 82 - 90
PARAMEL V G ET AL.: "NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis", J AM HEART ASSOC, vol. 5, no. 5, 20 May 2016 (2016-05-20), pages e003031
DUEWELL P ET AL.: "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals", NATURE, vol. 464, no. 7293, 29 April 2010 (2010-04-29), pages 1357 - 61, XP037202924, DOI: 10.1038/nature08938
BRODERICK L ET AL.: "The inflammasomes and autoinflammatory syndromes", ANNU REV PATHOL., vol. 10, 2015, pages 395 - 424, XP055320834, DOI: 10.1146/annurev-pathol-012414-040431
SARRAUSTE M C ET AL.: "INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations", NUCLEIC ACIDS RES., vol. 31, no. 1, 1 January 2003 (2003-01-01), pages 282 - 5
BRYDGES SD ET AL.: "Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies", J CLIN INVEST., vol. 123, no. 11, November 2013 (2013-11-01), pages 4695 - 705
JIANG H ET AL.: "Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders", J EXP MED., vol. 214, no. 11, 6 November 2017 (2017-11-06), pages 3219 - 3238, XP055704914, DOI: 10.1084/jem.20171419
WREE A ET AL.: "NLRP3 inflammasome activation is required for fibrosis development in NAFLD", J MOL MED (BERL, vol. 92, no. 10, October 2014 (2014-10-01), pages 1069 - 82, XP035407197, DOI: 10.1007/s00109-014-1170-1
SO AK ET AL.: "Inflammation in gout: mechanisms and therapeutic targets", NAT REV RHEUMATOL., vol. 13, no. 11, November 2017 (2017-11-01), pages 639 - 647
MARTINON F ET AL.: "Gout-associated uric acid crystals activate the NALP3 inflammasome", NATURE, vol. 440, no. 7081, 9 March 2006 (2006-03-09), pages 237 - 41
MARCHETTI C ET AL.: "NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis", ARTHRITIS RES THER., vol. 20, no. 1, 3 August 2018 (2018-08-03), pages 169
MATHEWS RJ ET AL.: "Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment", ANN RHEUM DIS., vol. 73, no. 6, June 2014 (2014-06-01), pages 1202 - 10
ZHANG Y ET AL.: "NLRP3 Inflammasome Plays an Important Role in the Pathogenesis of Collagen-Induced Arthritis", MEDIATORS INFLAMM., vol. 2016, 2016, pages 9656270
WATANABE H ET AL.: "Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity", J INVEST DERMATOL., vol. 127, no. 8, August 2007 (2007-08-01), pages 1956 - 63
NIU L ET AL.: "Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients", PLOS ONE, vol. 10, no. 5, 11 May 2015 (2015-05-11), pages e0126277
ZHENG Q ET AL.: "Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients", EXP EYE RES., vol. 134, May 2015 (2015-05-01), pages 133 - 40, XP029220145, DOI: 10.1016/j.exer.2015.02.013
KAWAGUCHI M ET AL.: "Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury", CIRCULATION, vol. 123, no. 6, 15 February 2011 (2011-02-15), pages 594 - 604
SANDANGER 0 ET AL.: "The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury", CARDIOVASC RES., vol. 99, no. 1, 1 July 2013 (2013-07-01), pages 164 - 74
DELLALIBERA-JOVILIANO R ET AL.: "Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus", J RHEUMATOL., vol. 30, no. 3, March 2003 (2003-03-01), pages 485 - 92
TUCCI M ET AL.: "Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18", ARTHRITIS RHEUM., vol. 58, no. 1, January 2008 (2008-01-01), pages 251 - 62
YANG CA ET AL.: "Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages", RHEUMATOLOGY (OXFORD, vol. 54, no. 2, February 2015 (2015-02-01), pages 324 - 31
LU A ET AL.: "Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus", J IMMUNOL., vol. 198, no. 3, 1 February 2017 (2017-02-01), pages 1119 - 1129
RUPERTO N ET AL.: "Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis", N ENGL J MED., vol. 367, no. 25, 20 December 2012 (2012-12-20), pages 2396 - 406
KLEIN AL ET AL.: "Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis", N ENGL J MED., vol. 384, no. 1, 7 January 2021 (2021-01-07), pages 31 - 41
JUNGE G ET AL.: "Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review", SEMINARS IN ARTHRITIS RHEUMATISM, vol. 47, no. 2, October 2017 (2017-10-01), pages 295 - 302
KRAUSE K ET AL.: "Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study", J ALLERGY CLIN IMMUNOL., vol. 139, no. 4, April 2017 (2017-04-01), pages 1311 - 1320, XP029967946, DOI: 10.1016/j.jaci.2016.07.041
GARG M ET AL.: "Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist", JCI INSIGHT., vol. 2, no. 16, 17 August 2017 (2017-08-17)
DE BENEDETTI F ET AL.: "Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes", N ENGL J MED., vol. 378, no. 20, 17 May 2018 (2018-05-17), pages 1908 - 1919
EMMI G ET AL.: "Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study", CLIN. RHEUMATOL., vol. 35, 2016, pages 1281 - 1286, XP035892558, DOI: 10.1007/s10067-015-3004-0
RIDKER P.M. ET AL.: "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease", LANCET, vol. 390, 2017, pages 1833 - 42
M CARLSTROM ET AL.: "Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility", EXP DERMATOL., vol. 21, 2012, pages 932 - 7, XP071776854, DOI: 10.1111/exd.12049
J. A DIAZ-PEREZ ET AL.: "Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis", J INVEST DERMATOL., vol. 138, 2018, pages 2595 - 605
WANG Q ET AL.: "Renin-Dependent Hypertension in Mice Requires the NLRP3-Inflammasome", J. HYPERTENS, vol. 3, 2014, pages 187
KRISHNAN S M ET AL.: "Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension", CARDIOVASC. RES., vol. 115, no. 4, 2019, pages 776 - 787
ZHANG Y ET AL.: "Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction", CELL DEATH DIS., vol. 8, no. 7, 20 July 2017 (2017-07-20), pages e2941
SHENG LI ET AL.: "Protective effects of sulforaphane on diabetic retinopathy: activation of the Nrf2 pathway and inhibition of NLRP3 inflammasome formation", EXP ANIM., vol. 68, no. 2, 8 May 2019 (2019-05-08), pages 221 - 231
GUANGRUI CHAI ET AL.: "NLRP3 Blockade Suppresses Pro-Inflammatory and Pro-Angiogenic Cytokine Secretion in Diabetic Retinopathy", DIABETES METAB SYNDR OBES, vol. 13, 25 August 2020 (2020-08-25), pages 3047 - 3058
HENEKA MT ET AL.: "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice", NATURE, vol. 493, no. 7434, 31 January 2013 (2013-01-31), pages 674 - 8, XP055125448, DOI: 10.1038/nature11729
DEMPSEY C ET AL.: "Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice", BRAIN BEHAV IMMUN., vol. 61, March 2017 (2017-03-01), pages 306 - 316, XP029920335, DOI: 10.1016/j.bbi.2016.12.014
GORDON R ET AL.: "Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice", SCI TRANSL MED., vol. 10, no. 465, 31 October 2018 (2018-10-31), pages eaah4066
RODRIGUES FB ET AL.: "Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease", PLOS ONE, vol. 11, no. 9, 22 September 2016 (2016-09-22), pages e0163479
PALDINO E ET AL.: "Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome", CELL DEATH DISCOV., vol. 6, 31 July 2020 (2020-07-31), pages 69
CHEN KP ET AL.: "A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease", J NEUROINFLAMMATION., vol. 19, no. 1, 26 February 2022 (2022-02-26), pages 56
JOHANN S ET AL.: "NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients", GLIA, vol. 63, no. 12, December 2015 (2015-12-01), pages 2260 - 73, XP071740366, DOI: 10.1002/glia.22891
DEORA V ET AL.: "The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins", GLIA, vol. 68, no. 2, February 2020 (2020-02-01), pages 407 - 421, XP071754600, DOI: 10.1002/glia.23728
MEISSNER F ET AL.: "A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis", PROC NATL ACAD SCI USA., vol. 107, no. 29, 20 July 2010 (2010-07-20), pages 13046 - 50, XP055759350, DOI: 10.1073/pnas.1002396107
LIN C ET AL.: "Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury", EXP NEUROL., vol. 290, April 2017 (2017-04-01), pages 115 - 122, XP029928396, DOI: 10.1016/j.expneurol.2017.01.005
WALLISCH JS ET AL.: "Cerebrospinal Fluid NLRP3 is Increased After Severe Traumatic Brain Injury in Infants and Children", NEUROCRIT CARE., vol. 27, no. 1, August 2017 (2017-08-01), pages 44 - 50, XP036286516, DOI: 10.1007/s12028-017-0378-7
LIU HD ET AL.: "Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model", NEUROCHEM RES, vol. 38, no. 10, October 2013 (2013-10-01), pages 2072 - 83
ISMAEL S ET AL.: "MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury", J NEUROTRAUMA., vol. 35, no. 11, 1 June 2018 (2018-06-01), pages 1294 - 1303
FANN DY ET AL.: "Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke", CELL DEATH DIS., vol. 4, no. 9, 5 September 2013 (2013-09-05), pages e790
FENG L ET AL.: "P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: involvement of peroxynitrite", J NEUROINFLAMMATION., vol. 12, 17 October 2015 (2015-10-17), pages 190, XP021230201, DOI: 10.1186/s12974-015-0409-2
YUE J ET AL.: "NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: molecular insights into their interdependence", NEUROPATHOL APPL NEUROBIOL., vol. 46, no. 7, pages 770 - 785
WU C ET AL.: "The Role of NLRP3 and IL-lβ in Refractory Epilepsy Brain Injury", FRONT NEUROL., no. 10, 7 February 2020 (2020-02-07), pages 1418
ALCOCER-GΔMEZ E ET AL.: "NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder", BRAIN BEHAV IMMUN., vol. 36, February 2014 (2014-02-01), pages 111 - 7
ZHANG Y ET AL.: "Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors", CNS NEUROSCI THER., vol. 20, no. 2, February 2014 (2014-02-01), pages 119 - 24
IWATA M ET AL.: "Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor", BIOL PSYCHIATRY., vol. 80, no. 1, 1 July 2016 (2016-07-01), pages 12 - 22, XP029599444, DOI: 10.1016/j.biopsych.2015.11.026
LI W ET AL.: "Inhibition of the NLRP3 inflammasome with MCC950 prevents chronic social isolation-induced depression-like behavior in male mice", NEUROSCI LETT., vol. 765, 20 November 2021 (2021-11-20), pages 136290
SARESELLA M ET AL.: "Multiple inflammasome complexes are activated in autistic spectrum disorders", BRAIN BEHAV IMMUN., vol. 57, October 2016 (2016-10-01), pages 125 - 133
SZABΔ D ET AL.: "Maternal P2X7 receptor inhibition prevents autism-like phenotype in male mouse offspring through the NLRP3-IL-lβ pathway", BRAIN BEHAV IMMUN., vol. 101, March 2022 (2022-03-01), pages 318 - 332, XP086969787, DOI: 10.1016/j.bbi.2022.01.015
AMO-APARICIO J ET AL.: "Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury", EXP NEUROL., vol. 347, January 2022 (2022-01-01), pages 113889
JIAO J ET AL.: "MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury", FRONT MOL BIOSCI., vol. 7, 3 March 2020 (2020-03-03), pages 37
DING H ET AL.: "Fisetin ameliorates cognitive impairment by activating mitophagy and suppressing neuroinflammation in rats with sepsis-associated encephalopathy", CNS NEUROSCI THER, vol. 28, no. 2, February 2022 (2022-02-01), pages 247 - 258
FU Q ET AL.: "NLRP3/Caspase-1 Pathway-Induced Pyroptosis Mediated Cognitive Deficits in a Mouse Model of Sepsis-Associated Encephalopathy", INFLAMMATION, vol. 42, no. 1, February 2019 (2019-02-01), pages 306 - 318, XP036779035, DOI: 10.1007/s10753-018-0894-4
XU L ET AL.: "MiR-34c Ameliorates Neuropathic Pain by Targeting NLRP3 in a Mouse Model of Chronic Constriction Injury", NEUROSCIENCE, vol. 399, 10 February 2019 (2019-02-10), pages 125 - 134, XP085580082, DOI: 10.1016/j.neuroscience.2018.12.030
JIA M ET AL.: "Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain", MOL PAIN., vol. 13, January 2017 (2017-01-01), pages 1744806917719804
SUN X ET AL.: "The NLRP3-related inflammasome modulates pain behavior in a rat model of trigeminal neuropathic pain", LIFE SCI, vol. 277, 15 July 2021 (2021-07-15), pages 119489
ZENG J ET AL.: "Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice", EBIOMEDICINE, vol. 75, January 2022 (2022-01-01), pages 103803
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages l-19
STAHL ET AL.: "Handbook of Pharmaceutical Salt: Properties, Selection, and Use", 2002, WILEY-VCH
PAULEKUHN ET AL., J. MED. CHEM., vol. 50, 2007, pages 6665 - 6672
ANDERSSON, A ET AL.: "Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis", J LEUKOC BIOL., vol. 84, no. 5, 2008, pages 1248 - 55, XP002659931, DOI: 10.1189/jlb.1207844
VOET, S ET AL.: "A20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation", NAT COMMUN., vol. 9, no. 1, 2018, pages 2036, XP055864050, DOI: 10.1038/s41467-018-04376-5
POLITIS, M ET AL.: "Increased PK11195 PET binding in the cortex of patients with MS correlates with disability", NEUROLOGY, vol. 79, no. 6, 2012, pages 523 - 30
HERNANDEZ-PEDRO, N ET AL.: "PAMP-DAMPs interactions mediates development and progression of multiple sclerosis", FRONT BIOSCI (SCHOL ED, vol. 8, 2016, pages 13 - 28
DENIS, G ET AL.: "NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses", J IMMUNOL., vol. 185, no. 2, 2010, pages 974 - 981
JHA, S ET AL.: "The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18", J NEUROSCI., vol. 30, no. 47, 2010, pages 15811 - 20, XP002661303, DOI: 10.1523/jneurosci.4088-10.2010
GUO, C ET AL.: "Development and Characterization of a Hydroxyl-Sulfonamide Analogue, 5-Chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a Novel NLRP3 Inflammasome Inhibitor for Potential Treatment of Multiple Sclerosis", ACS CHEM NEUROSCI., vol. 8, no. 10, 2017, pages 2194 - 2201, XP055509994, DOI: 10.1021/acschemneuro.7b00124
AKOSUA VILAYSANE ET AL.: "The NLRP3 Inflammasome Promotes Renal Inflammation and Contributes to CKD", J AM SOC NEPHROL., vol. 21, no. 10, October 2010 (2010-10-01), pages 1732 - 1744
SHAHZAD K ET AL.: "Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy", KIDNEY INT., vol. 87, no. 1, January 2015 (2015-01-01), pages 74 - 84, XP055881761, DOI: 10.1038/ki.2014.271
GONG W ET AL.: "NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy", AM J PHYSIOL RENAL PHYSIOL., vol. 310, no. 10, 15 May 2016 (2016-05-15), pages F1081 - 8
RANSON N ET AL.: "NLRP3-dependent and -independent processing Interleiukin-ip in active Ulcerative colitis", INT J MOL SCI, vol. 20, 2018, pages E57
MAO L ET AL.: "Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease", J CLIN INVEST, vol. 128, 2018, pages 1793 - 1806
BAUER C. ET AL.: "Protective and aggravating effects of NLRP3 inlammasome activation in IBD models : influence of genetic and environmental factors", DIG.DIS, vol. 30, 2012, pages 82 - 90
PARAMEL V G ET AL.: "NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis", J AM HEART ASSOC, vol. 5, no. 5, 20 May 2016 (2016-05-20), pages e003031
DUEWELL P ET AL.: "NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals", NATURE, vol. 464, no. 7293, 29 April 2010 (2010-04-29), pages 1357 - 61, XP037202924, DOI: 10.1038/nature08938
BRODERICK L ET AL.: "The inflammasomes and autoinflammatory syndromes", ANNU REV PATHOL., vol. 10, 2015, pages 395 - 424, XP055320834, DOI: 10.1146/annurev-pathol-012414-040431
SARRAUSTE M C ET AL.: "INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations", NUCLEIC ACIDS RES., vol. 31, no. 1, 1 January 2003 (2003-01-01), pages 282 - 5
BRYDGES SD ET AL.: "Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies", J CLIN INVEST., vol. 123, no. 11, November 2013 (2013-11-01), pages 4695 - 705
JIANG H ET AL.: "Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders", J EXP MED., vol. 214, no. 11, 6 November 2017 (2017-11-06), pages 3219 - 3238, XP055704914, DOI: 10.1084/jem.20171419
WREE A ET AL.: "NLRP3 inflammasome activation is required for fibrosis development in NAFLD", J MOL MED (BERL, vol. 92, no. 10, October 2014 (2014-10-01), pages 1069 - 82, XP035407197, DOI: 10.1007/s00109-014-1170-1
SO AK ET AL.: "Inflammation in gout: mechanisms and therapeutic targets", NAT REV RHEUMATOL., vol. 13, no. 11, November 2017 (2017-11-01), pages 639 - 647
MARTINON F ET AL.: "Gout-associated uric acid crystals activate the NALP3 inflammasome", NATURE, vol. 440, no. 7081, 9 March 2006 (2006-03-09), pages 237 - 41
MARCHETTI C ET AL.: "NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis", ARTHRITIS RES THER., vol. 20, no. 1, 3 August 2018 (2018-08-03), pages 169
MATHEWS RJ ET AL.: "Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment", ANN RHEUM DIS., vol. 73, no. 6, June 2014 (2014-06-01), pages 1202 - 10
ZHANG Y ET AL.: "NLRP3 Inflammasome Plays an Important Role in the Pathogenesis of Collagen-Induced Arthritis", MEDIATORS INFLAMM., vol. 2016, 2016, pages 9656270
WATANABE H ET AL.: "Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity", J INVEST DERMATOL., vol. 127, no. 8, August 2007 (2007-08-01), pages 1956 - 63
NIU L ET AL.: "Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients", PLOS ONE, vol. 10, no. 5, 11 May 2015 (2015-05-11), pages e0126277
ZHENG Q ET AL.: "Reactive oxygen species activated NLRP3 inflammasomes initiate inflammation in hyperosmolarity stressed human corneal epithelial cells and environment-induced dry eye patients", EXP EYE RES., vol. 134, May 2015 (2015-05-01), pages 133 - 40, XP029220145, DOI: 10.1016/j.exer.2015.02.013
KAWAGUCHI M ET AL.: "Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury", CIRCULATION, vol. 123, no. 6, 15 February 2011 (2011-02-15), pages 594 - 604
SANDANGER 0 ET AL.: "The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury", CARDIOVASC RES., vol. 99, no. 1, 1 July 2013 (2013-07-01), pages 164 - 74
DELLALIBERA-JOVILIANO R ET AL.: "Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus", J RHEUMATOL., vol. 30, no. 3, March 2003 (2003-03-01), pages 485 - 92
TUCCI M ET AL.: "Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18", ARTHRITIS RHEUM., vol. 58, no. 1, January 2008 (2008-01-01), pages 251 - 62
YANG CA ET AL.: "Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages", RHEUMATOLOGY (OXFORD, vol. 54, no. 2, February 2015 (2015-02-01), pages 324 - 31
LU A ET AL.: "Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus", J IMMUNOL., vol. 198, no. 3, 1 February 2017 (2017-02-01), pages 1119 - 1129
RUPERTO N ET AL.: "Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis", N ENGL J MED., vol. 367, no. 25, 20 December 2012 (2012-12-20), pages 2396 - 406
KLEIN AL ET AL.: "Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis", N ENGL J MED., vol. 384, no. 1, 7 January 2021 (2021-01-07), pages 31 - 41
JUNGE G ET AL.: "Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review", SEMINARS IN ARTHRITIS RHEUMATISM, vol. 47, no. 2, October 2017 (2017-10-01), pages 295 - 302
KRAUSE K ET AL.: "Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study", J ALLERGY CLIN IMMUNOL., vol. 139, no. 4, April 2017 (2017-04-01), pages 1311 - 1320, XP029967946, DOI: 10.1016/j.jaci.2016.07.041
GARG M ET AL.: "Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist", JCI INSIGHT., vol. 2, no. 16, 17 August 2017 (2017-08-17)
DE BENEDETTI F ET AL.: "Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes", N ENGL J MED., vol. 378, no. 20, 17 May 2018 (2018-05-17), pages 1908 - 1919
EMMI G ET AL.: "Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study", CLIN. RHEUMATOL., vol. 35, 2016, pages 1281 - 1286, XP035892558, DOI: 10.1007/s10067-015-3004-0
RIDKER P.M. ET AL.: "Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease", LANCET, vol. 390, 2017, pages 1833 - 42
M CARLSTROM ET AL.: "Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility", EXP DERMATOL., vol. 21, 2012, pages 932 - 7, XP071776854, DOI: 10.1111/exd.12049
J. A DIAZ-PEREZ ET AL.: "Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis", J INVEST DERMATOL., vol. 138, 2018, pages 2595 - 605
WANG Q ET AL.: "Renin-Dependent Hypertension in Mice Requires the NLRP3-Inflammasome", J. HYPERTENS, vol. 3, 2014, pages 187
KRISHNAN S M ET AL.: "Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension", CARDIOVASC. RES., vol. 115, no. 4, 2019, pages 776 - 787
ZHANG Y ET AL.: "Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction", CELL DEATH DIS., vol. 8, no. 7, 20 July 2017 (2017-07-20), pages e2941
SHENG LI ET AL.: "Protective effects of sulforaphane on diabetic retinopathy: activation of the Nrf2 pathway and inhibition of NLRP3 inflammasome formation", EXP ANIM., vol. 68, no. 2, 8 May 2019 (2019-05-08), pages 221 - 231
GUANGRUI CHAI ET AL.: "NLRP3 Blockade Suppresses Pro-Inflammatory and Pro-Angiogenic Cytokine Secretion in Diabetic Retinopathy", DIABETES METAB SYNDR OBES, vol. 13, 25 August 2020 (2020-08-25), pages 3047 - 3058
HENEKA MT ET AL.: "NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice", NATURE, vol. 493, no. 7434, 31 January 2013 (2013-01-31), pages 674 - 8, XP055125448, DOI: 10.1038/nature11729
DEMPSEY C ET AL.: "Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice", BRAIN BEHAV IMMUN., vol. 61, March 2017 (2017-03-01), pages 306 - 316, XP029920335, DOI: 10.1016/j.bbi.2016.12.014
GORDON R ET AL.: "Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice", SCI TRANSL MED., vol. 10, no. 465, 31 October 2018 (2018-10-31), pages eaah4066
RODRIGUES FB ET AL.: "Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease", PLOS ONE, vol. 11, no. 9, 22 September 2016 (2016-09-22), pages e0163479
PALDINO E ET AL.: "Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome", CELL DEATH DISCOV., vol. 6, 31 July 2020 (2020-07-31), pages 69
CHEN KP ET AL.: "A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease", J NEUROINFLAMMATION., vol. 19, no. 1, 26 February 2022 (2022-02-26), pages 56
JOHANN S ET AL.: "NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients", GLIA, vol. 63, no. 12, December 2015 (2015-12-01), pages 2260 - 73, XP071740366, DOI: 10.1002/glia.22891
DEORA V ET AL.: "The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins", GLIA, vol. 68, no. 2, February 2020 (2020-02-01), pages 407 - 421, XP071754600, DOI: 10.1002/glia.23728
MEISSNER F ET AL.: "A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis", PROC NATL ACAD SCI USA., vol. 107, no. 29, 20 July 2010 (2010-07-20), pages 13046 - 50, XP055759350, DOI: 10.1073/pnas.1002396107
LIN C ET AL.: "Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury", EXP NEUROL., vol. 290, April 2017 (2017-04-01), pages 115 - 122, XP029928396, DOI: 10.1016/j.expneurol.2017.01.005
WALLISCH JS ET AL.: "Cerebrospinal Fluid NLRP3 is Increased After Severe Traumatic Brain Injury in Infants and Children", NEUROCRIT CARE., vol. 27, no. 1, August 2017 (2017-08-01), pages 44 - 50, XP036286516, DOI: 10.1007/s12028-017-0378-7
LIU HD ET AL.: "Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model", NEUROCHEM RES, vol. 38, no. 10, October 2013 (2013-10-01), pages 2072 - 83
ISMAEL S ET AL.: "MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury", J NEUROTRAUMA., vol. 35, no. 11, 1 June 2018 (2018-06-01), pages 1294 - 1303
FANN DY ET AL.: "Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke", CELL DEATH DIS., vol. 4, no. 9, 5 September 2013 (2013-09-05), pages e790
FENG L ET AL.: "P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: involvement of peroxynitrite", J NEUROINFLAMMATION., vol. 12, 17 October 2015 (2015-10-17), pages 190, XP021230201, DOI: 10.1186/s12974-015-0409-2
YUE J ET AL.: "NLRP3 inflammasome and endoplasmic reticulum stress in the epileptogenic zone in temporal lobe epilepsy: molecular insights into their interdependence", NEUROPATHOL APPL NEUROBIOL., vol. 46, no. 7, pages 770 - 785
WU C ET AL.: "The Role of NLRP3 and IL-lβ in Refractory Epilepsy Brain Injury", FRONT NEUROL., no. 10, 7 February 2020 (2020-02-07), pages 1418
ALCOCER-GΔMEZ E ET AL.: "NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder", BRAIN BEHAV IMMUN., vol. 36, February 2014 (2014-02-01), pages 111 - 7
ZHANG Y ET AL.: "Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors", CNS NEUROSCI THER., vol. 20, no. 2, February 2014 (2014-02-01), pages 119 - 24
IWATA M ET AL.: "Psychological Stress Activates the Inflammasome via Release of Adenosine Triphosphate and Stimulation of the Purinergic Type 2X7 Receptor", BIOL PSYCHIATRY., vol. 80, no. 1, 1 July 2016 (2016-07-01), pages 12 - 22, XP029599444, DOI: 10.1016/j.biopsych.2015.11.026
LI W ET AL.: "Inhibition of the NLRP3 inflammasome with MCC950 prevents chronic social isolation-induced depression-like behavior in male mice", NEUROSCI LETT., vol. 765, 20 November 2021 (2021-11-20), pages 136290
SARESELLA M ET AL.: "Multiple inflammasome complexes are activated in autistic spectrum disorders", BRAIN BEHAV IMMUN., vol. 57, October 2016 (2016-10-01), pages 125 - 133
SZABΔ D ET AL.: "Maternal P2X7 receptor inhibition prevents autism-like phenotype in male mouse offspring through the NLRP3-IL-lβ pathway", BRAIN BEHAV IMMUN., vol. 101, March 2022 (2022-03-01), pages 318 - 332, XP086969787, DOI: 10.1016/j.bbi.2022.01.015
AMO-APARICIO J ET AL.: "Inhibition of the NLRP3 inflammasome by OLT1177 induces functional protection and myelin preservation after spinal cord injury", EXP NEUROL., vol. 347, January 2022 (2022-01-01), pages 113889
JIAO J ET AL.: "MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury", FRONT MOL BIOSCI., vol. 7, 3 March 2020 (2020-03-03), pages 37
DING H ET AL.: "Fisetin ameliorates cognitive impairment by activating mitophagy and suppressing neuroinflammation in rats with sepsis-associated encephalopathy", CNS NEUROSCI THER, vol. 28, no. 2, February 2022 (2022-02-01), pages 247 - 258
FU Q ET AL.: "NLRP3/Caspase-1 Pathway-Induced Pyroptosis Mediated Cognitive Deficits in a Mouse Model of Sepsis-Associated Encephalopathy", INFLAMMATION, vol. 42, no. 1, February 2019 (2019-02-01), pages 306 - 318, XP036779035, DOI: 10.1007/s10753-018-0894-4
XU L ET AL.: "MiR-34c Ameliorates Neuropathic Pain by Targeting NLRP3 in a Mouse Model of Chronic Constriction Injury", NEUROSCIENCE, vol. 399, 10 February 2019 (2019-02-10), pages 125 - 134, XP085580082, DOI: 10.1016/j.neuroscience.2018.12.030
JIA M ET AL.: "Activation of NLRP3 inflammasome in peripheral nerve contributes to paclitaxel-induced neuropathic pain", MOL PAIN., vol. 13, January 2017 (2017-01-01), pages 1744806917719804
SUN X ET AL.: "The NLRP3-related inflammasome modulates pain behavior in a rat model of trigeminal neuropathic pain", LIFE SCI, vol. 277, 15 July 2021 (2021-07-15), pages 119489
ZENG J ET AL.: "Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice", EBIOMEDICINE, vol. 75, January 2022 (2022-01-01), pages 103803
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages l-19
STAHL ET AL.: "Handbook of Pharmaceutical Salt: Properties, Selection, and Use", 2002, WILEY-VCH
PAULEKUHN ET AL., J. MED. CHEM., vol. 50, 2007, pages 6665 - 6672
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF:
Previous Patent: SILICA FOR ELECTRONIC MATERIALS AND METHOD FOR PRODUCING SAME
Next Patent: PRESSING RING, PIPE JOINT, AND METHOD FOR JOINING PIPES
Next Patent: PRESSING RING, PIPE JOINT, AND METHOD FOR JOINING PIPES